Lucid Diligence Brief: Axoft $55 million Series A
Lucid Diligence Brief: Axoft $55 million Series A Professional audiences only.…
Lucid Diligence Brief: Teva to acquire Emalex Biosciences
Lucid Diligence Brief: Teva to acquire Emalex Biosciences Professional…
Lucid Diligence Brief: Viz.ai and Johnson & Johnson collaboration on AI-powered subdural hemorrhage care
Lucid Diligence Brief: Viz.ai and Johnson & Johnson collaboration on…
Lucid Diligence Brief: CellCarta and Pillar Biosciences strategic partnership
Lucid Diligence Brief: CellCarta and Pillar Biosciences strategic partnership…
Hematology Today—March 23, 2026
This week’s Hematology update highlights hemophilia gene therapy supply…
Lucid Diligence Brief: Cognito Therapeutics $105 million Series C
Lucid Diligence Brief: Cognito Therapeutics $105 million Series C Professional…
Lucid Diligence Brief: Poplar Therapeutics $95 million Series A
Lucid Diligence Brief: Poplar Therapeutics $95 million Series A extension…
Rare Diseases Today—February 26, 2026
This week's Rare Disease update summarizes regulatory actions (orphan…
Endocrinology Today—February 24, 2026
This week's Endocrinology update covers guideline and labeling changes,…
Lucid Diligence Brief: Gilead to acquire Arcellx (anito-cel)
Lucid Diligence Brief: Gilead to acquire Arcellx (anito-cel) Professional…
Lucid Diligence Brief: Candel Therapeutics $100m funding for CAN-2409 in localized prostate cancer
Lucid Diligence Brief: Candel Therapeutics $100m funding for CAN-2409 in…
Oncology Video Recap—February 16, 2026
This biweekly Oncology video recap is covering key developments across the…